Parker Javid - Lifecore Biomedical Vice President
| LFCR Stock | 7.46 0.15 2.05% |
President
Parker Javid is Vice President of Lifecore Biomedical
| Age | 55 |
| Address | 3515 Lyman Boulevard, Chaska, MN, United States, 55318 |
| Phone | (952) 368-4300 |
| Web | https://www.lifecore.com |
Lifecore Biomedical Management Efficiency
The company has return on total asset (ROA) of (0.0225) % which means that it has lost $0.0225 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1729 %, meaning that it created $0.1729 on every $100 dollars invested by stockholders. Lifecore Biomedical's management efficiency ratios could be used to measure how well Lifecore Biomedical manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/26/2024, Return On Tangible Assets is likely to drop to -0.02. In addition to that, Return On Capital Employed is likely to drop to 0.02. At this time, Lifecore Biomedical's Non Currrent Assets Other are relatively stable compared to the past year. As of 11/26/2024, Total Current Assets is likely to grow to about 86.2 M, while Non Current Assets Total are likely to drop slightly above 161.8 M.Similar Executives
| Found 14 records | PRESIDENT Age | ||
| Jonathan Arnold | Catalent | 54 | |
| Charles Lickfold | Catalent | 50 | |
| Wetteny Joseph | Catalent | 48 | |
| Alessandro Maselli | Catalent | 52 | |
| Ricky Hopson | Catalent | 48 | |
| Ricardo Pravda | Catalent | 48 | |
| Tom PEng | Catalent | 56 | |
| Scott Gunther | Catalent | 52 | |
| Steven Fasman | Catalent | 57 | |
| Aristippos Gennadios | Catalent | 58 | |
| Ty Gilmore | Tilray Inc | N/A | |
| CPA CMA | Tilray Inc | N/A | |
| MD MBA | Shuttle Pharmaceuticals | 55 | |
| Trish Hunt | Catalent | 54 | |
Management Performance
| Return On Equity | 0.17 | ||||
| Return On Asset | -0.0225 |
Lifecore Biomedical Leadership Team
Elected by the shareholders, the Lifecore Biomedical's board of directors comprises two types of representatives: Lifecore Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lifecore. The board's role is to monitor Lifecore Biomedical's management team and ensure that shareholders' interests are well served. Lifecore Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lifecore Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Darren Hieber, Senior Partnerships | ||
| Parker Javid, Vice President | ||
| Matt Augustson, Senior Technology | ||
| Aaron Perlitsh, Director Officer | ||
| James Hall, President CEO | ||
| Kara Morley, Senior Resources | ||
| Brikkelle Thompson, Senior Resources | ||
| John Morberg, Executive CFO | ||
| Paul Josephs, CEO President | ||
| Steve Laninga, Vice Operations | ||
| Jackie Klecker, Executive GM | ||
| Kipling Thacker, VP Scientist | ||
| Ryan CPA, CFO Secretary | ||
| Albert Bolles, I Foods |
Lifecore Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lifecore Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | ||||
| Return On Asset | -0.0225 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | (0.37) % | ||||
| Current Valuation | 400.55 M | ||||
| Shares Outstanding | 36.83 M | ||||
| Shares Owned By Insiders | 5.31 % | ||||
| Shares Owned By Institutions | 69.57 % | ||||
| Number Of Shares Shorted | 2.57 M | ||||
| Price To Book | 15.35 X |
Pair Trading with Lifecore Biomedical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifecore Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifecore Biomedical will appreciate offsetting losses from the drop in the long position's value.Moving against Lifecore Stock
| 0.8 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.79 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.79 | TCHH | Trustcash Holdings | PairCorr |
| 0.78 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.76 | AGL | agilon health Buyout Trend | PairCorr |
The ability to find closely correlated positions to Lifecore Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifecore Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifecore Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifecore Biomedical to buy it.
The correlation of Lifecore Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifecore Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifecore Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifecore Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.